Skip to main content

Illumina stock price and financials

  • ILMN · Nasdaq
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$198.26−4.22%Close 16 Nov 2026
Market value
$30.43B
P/E
34.00
EV / EBITDA
25.02
Beta · 1 year
1.10
Return · 1 year
+65.3%
52-week range$112.65 — $309.35

Share price close 16 Nov 2026

−25.1%1 monthHigh $290.06Low $200.66
$200$225$250$275$300Q3 FY2026 report filed 30 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+40.8%6 monthsHigh $293.69Low $141.51
$100$150$200$250$300Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+53.0%year to dateHigh $293.69Low $114.44
$100$150$200$250$300Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 4 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+66.3%1 yearHigh $293.69Low $114.44
$100$150$200$250$300Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 4 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+106%3 yearsHigh $293.69Low $70.30
$0$100$200$300Q4 FY2023 report filed 16 Feb 2024Q1 FY2024 report filed 3 May 2024Q2 FY2024 report filed 7 Aug 2024Q3 FY2024 report filed 6 Nov 2024Q4 FY2024 report filed 12 Feb 2025Q1 FY2025 report filed 9 May 2025Q2 FY2025 report filed 1 Aug 2025Q3 FY2025 report filed 31 Oct 2025Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 4 May 2026Q2 FY2026 report filed 31 Jul 2026Q3 FY2026 report filed 30 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+56.4%10 yearsHigh $503.23Low $70.30
$0$200$400$600Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Illumina reported revenue of $4.34 billion for fiscal year 2025 (the twelve months to 28 Dec 2025), down 0.7% from fiscal 2024. Net income was $850 million and diluted earnings per share $5.45.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 27 Sep 2026), revenue was $1.13 billion, up 4.2% from a year earlier.

Figures from Illumina's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.

Against Health Care

Growth
Lower half
Revenue +6.1% a year over five years · 24th of 37
Profitability
Bottom quarter
Return on invested capital -7.3%, five-year average · 38th of 38
Balance sheet
Upper half
Net debt 0.8× EBITDA · 12th of 38
Valuation
Above the median
P/E 34.0 · 21st of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$4.34B−0.7%
Net income
$850.0M
Diluted EPS
$5.45
Gross margin
66.1%+0.6 pts
Free cash flow
$931.0M+31.3%
Net debt
$920.0M−34.4%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
−$6B−$4B−$2B$0$2B$4B$6BRevenue, FY16: $2.4BNet income, FY16: $463MFY16Revenue, FY17: $2.75BNet income, FY17: $726MFY17Revenue, FY18: $3.33BNet income, FY18: $826MFY18Revenue, FY19: $3.54BNet income, FY19: $1BFY19Revenue, FY20: $3.24BNet income, FY20: $656MFY20Revenue, FY21: $4.53BNet income, FY21: $762MFY21Revenue, FY22: $4.58BNet income, FY22: −$4.4BFY22Revenue, FY23: $4.5BNet income, FY23: −$1.16BFY23Revenue, FY24: $4.37BNet income, FY24: −$1.22BFY24Revenue, FY25: $4.34BNet income, FY25: $850MFY25

Latest quarter · Q3 FY2026 to 27 Sep 2026, filed 30 Oct 2026 · Full results →

Revenue
$1.13B+4.2% on a year
Gross margin
73.5%+5.9 pts on a year
Operating income
$305.0M+34.4% on a year
Net income
$220.0M+46.7% on a year
Diluted EPS
$1.43+45.9% on a year
Free cash flow
$379.0M+49.8% on a year

Comparable companies All of Health Care →

Illumina beside the other S&P 500 members in Life Sciences Tools & Services, by market value.

Illumina and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
IlluminaILMN$30.43B−4.2%+65.3%+5.8%19.7%34.0
Danaher CorporationDHR$163.0B+0.4%+6.2%+5.5%16.9%37.6
Agilent TechnologiesA$48.72B+0.5%+14.8%+8.6%19.5%33.8
IQVIAIQV$43.52B−2.2%+20.0%+8.8%8.1%31.2
Charles River LaboratoriesCRL$16.06B−0.8%+97.1%−1.2%1.0%399.6
Bio-TechneTECH—−0.1%+18.6%———
Mettler ToledoMTD—+0.5%+20.1%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
-100%0%100%66.1%19.6%18.6%FY16FY19FY22FY25

Illumina revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Illumina revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Sequencing$4.11B$4.17B+1.5%$4.11B−1.4%$3.99B−2.9%$3.98B−0.2%
Microarray$417.0M$413.0M−1.0%$392.0M−5.1%$379.0M−3.3%$358.0M−5.5%
Total revenue$4.53B$4.58B$4.50B$4.37B$4.34B

By product

Illumina revenue by product, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Consumables$3.22B$3.23B+0.2%$3.08B−4.4%$3.15B+2.3%$3.23B+2.3%
Service$558.0M$631.0M+13.1%$717.0M+13.6%$716.0M−0.1%$634.0M−11.5%
Instruments$751.0M$728.0M−3.1%$704.0M−3.3%$501.0M−28.8%$482.0M−3.8%
Total revenue$4.53B$4.58B$4.50B$4.37B$4.34B

By region

Illumina revenue by region, by fiscal year
RevenueFY 2018FY 2019FY 2020FY 2021FY 2022
Americas$1.86B$1.97B+5.7%$1.74B−11.5%$2.36B+35.2%$2.48B+5.1%
Europe, Middle East, Africa and Latin America$851.0M$933.0M+9.6%$886.0M−5.0%$1.29B+45.5%$1.22B−5.7%
China$365.0M$372.0M+1.9%$342.0M−8.1%$502.0M+46.8%$472.0M−6.0%
Asia-Pacific$253.0M$268.0M+5.9%$267.0M−0.4%$377.0M+41.2%$418.0M+10.9%
Total revenue$3.33B$3.54B$3.24B$4.53B$4.58B

Financial statements

Fiscal years, the latest ending 28 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Illumina income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$2.40B$2.75B$3.33B$3.54B$3.24B$4.53B$4.58B$4.50B$4.37B$4.34B
Revenue growth+8.0%+14.8%+21.1%+6.3%−8.6%+39.7%+1.3%−1.7%−2.9%−0.7%
Gross profit$1.67B$1.83B$2.30B$2.47B$2.20B$3.15B$2.97B$2.74B$2.86B$2.87B
Operating income$587.0M$606.0M$883.0M$985.0M$580.0M−$123.0M−$4.18B−$1.07B−$833.0M$807.0M
Net income$463.0M$726.0M$826.0M$1.00B$656.0M$762.0M−$4.40B−$1.16B−$1.22B$850.0M
Diluted EPS$3.07$4.92$5.56$6.74$4.45$5.04−$28.00−$7.34−$7.69$5.45
Gross margin69.5%66.4%69.0%69.6%68.0%69.7%64.8%60.9%65.4%66.1%
Operating margin24.5%22.0%26.5%27.8%17.9%−2.7%−91.2%−23.7%−19.1%18.6%
Net margin19.3%26.4%24.8%28.3%20.3%16.8%−96.1%−25.8%−28.0%19.6%

Cash flow

Illumina cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$779.0M$875.0M$1.14B$1.05B$1.08B$545.0M$392.0M$478.0M$837.0M$1.08B
Capital expenditure$260.0M$310.0M$296.0M$209.0M$189.0M$208.0M$286.0M$195.0M$128.0M$148.0M
Free cash flow$519.0M$565.0M$846.0M$842.0M$891.0M$337.0M$106.0M$283.0M$709.0M$931.0M

Balance sheet and shares

Illumina balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$735.0M$1.23B$1.14B$2.04B$1.81B$1.23B$2.01B$1.05B$1.13B$1.42B
Total debt$1.06B$1.19B$2.00B$1.88B$1.91B$1.55B$1.57B$2.26B$2.62B$2.55B
Shareholders' equity$2.20B$2.75B$3.76B$4.61B$4.69B$10.74B$6.60B$5.75B$2.37B$2.72B
Diluted shares148M148M149M149M148M151M157M158M159M156M

Quarterly figures

The last eight fiscal quarters, the latest ending 27 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Illumina quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.10B$1.04B$1.06B$1.08B$1.16B$1.09B$1.16B$1.13B
Revenue, year on year−1.6%−3.3%−4.8%+0.4%+5.0%+4.8%+9.4%+4.2%
Gross margin65.9%65.6%65.6%67.6%65.5%66.1%66.4%73.5%
Operating income$175.0M$164.0M$214.0M$227.0M$201.0M$209.0M$245.0M$305.0M
Net income$186.0M$131.0M$235.0M$150.0M$334.0M$134.0M$207.0M$220.0M
Diluted EPS$1.17$0.82$1.49$0.98$2.18$0.87$1.35$1.43
Free cash flow$335.0M$208.0M$204.0M$253.0M$266.0M$251.0M$161.0M$379.0M

Operating KPIs

The operating figures Illumina reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Illumina operating KPIs
KPILatestPeriodChange on a yearRecent periods
Consumables revenue$841.0Mquarter to 27 Sep 2026up 3.1%
Service revenue$183.0Mquarter to 27 Sep 2026up 16.6%
Instruments revenue$105.0Mquarter to 27 Sep 2026down 5.4%
Core Illumina revenue$1.1Bquarter to 27 Sep 2026up 4.2%
Sequencing revenue$1.0Bquarter to 27 Sep 2026up 2.0%
Microarray revenue$108.0Mquarter to 27 Sep 2026up 30.1%
Americas revenue$638.0Mquarter to 28 Dec 2025up 8.3%
Europe revenue$353.0Mquarter to 28 Dec 2025up 8.3%
Asia-Pacific, Middle East and Africa revenue$112.0Mquarter to 28 Dec 2025up 2.8%
China revenue$59.0Mquarter to 27 Sep 2026up 13.5%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Illumina's revenue in fiscal 2025?

$4.34 billion for fiscal year 2025 (the twelve months to 28 Dec 2025), as reported in its annual report.

What was Illumina's net income in fiscal 2025?

$850 million for fiscal year 2025 (the twelve months to 28 Dec 2025).

What were Illumina's diluted earnings per share in fiscal 2025?

$5.45 for fiscal year 2025 (the twelve months to 28 Dec 2025).

What is Illumina's gross margin?

66.1% for fiscal year 2025 (the twelve months to 28 Dec 2025): gross profit divided by revenue.

What is Illumina's operating margin?

18.6% for fiscal year 2025 (the twelve months to 28 Dec 2025): operating income divided by revenue.

How much free cash flow did Illumina generate in fiscal 2025?

$931 million for fiscal year 2025 (the twelve months to 28 Dec 2025): operating cash flow less capital expenditure.

Where does Illumina's revenue come from?

In fiscal 2025, by segment: Sequencing $3.98B (92%), Microarray $358.0M (8.2%), GRAIL $0.00 (0.0%), out of $4.34B in all, as stated in its annual report.

In the terminal

Twenty years of Illumina's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans